Literature DB >> 26071007

The Global Virus Network: Challenging chikungunya.

Edward McSweegan1, Scott C Weaver2, Marc Lecuit3, Matthew Frieman4, Thomas E Morrison5, Sharon Hrynkow6.   

Abstract

The recent spread of chikungunya virus to the Western Hemisphere, together with the ongoing Ebola epidemic in West Africa, have highlighted the importance of international collaboration in the detection and management of disease outbreaks. In response to this need, the Global Virus Network (GVN) was formed in 2011. The GVN is a coalition of leading medical virologists in 34 affiliated laboratories in 24 countries, who collaborate to share their resources and expertise. The GVN supports research, promotes training for young scientists, serves as a technical resource for governments, businesses and international organizations, facilitates international scientific cooperation, and advocates for funding and evidence-based public policies. In response to the spread of chikungunya, the GVN formed a task force to identify research gaps and opportunities, including models of infection and disease, candidate vaccines and antivirals, epidemiology and vector control measures. Its members also serve as authoritative sources of information for the public, press, and policy-makers. This article forms part of a symposium in Antiviral Research on "Chikungunya discovers the New World". Published by Elsevier B.V.

Entities:  

Keywords:  Arbovirus; Chikungunya; Emerging virus; Global Virus Network; Vector-borne

Mesh:

Year:  2015        PMID: 26071007      PMCID: PMC4843800          DOI: 10.1016/j.antiviral.2015.06.003

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  37 in total

1.  Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose.

Authors:  Chad J Roy; A Paige Adams; Eryu Wang; Kenneth Plante; Rodion Gorchakov; Robert L Seymour; Heather Vinet-Oliphant; Scott C Weaver
Journal:  J Infect Dis       Date:  2014-01-07       Impact factor: 5.226

Review 2.  Chikungunya: Evolutionary history and recent epidemic spread.

Authors:  Scott C Weaver; Naomi L Forrester
Journal:  Antiviral Res       Date:  2015-05-12       Impact factor: 5.970

3.  Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.

Authors:  R Edelman; C O Tacket; S S Wasserman; S A Bodison; J G Perry; J A Mangiafico
Journal:  Am J Trop Med Hyg       Date:  2000-06       Impact factor: 2.345

4.  Bindarit, an inhibitor of monocyte chemotactic protein synthesis, protects against bone loss induced by chikungunya virus infection.

Authors:  Weiqiang Chen; Suan-Sin Foo; Adam Taylor; Aleksei Lulla; Andres Merits; Linda Hueston; Mark R Forwood; Nicole C Walsh; Natalie A Sims; Lara J Herrero; Suresh Mahalingam
Journal:  J Virol       Date:  2014-10-22       Impact factor: 5.103

5.  Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial.

Authors:  Lee-Jah Chang; Kimberly A Dowd; Floreliz H Mendoza; Jamie G Saunders; Sandra Sitar; Sarah H Plummer; Galina Yamshchikov; Uzma N Sarwar; Zonghui Hu; Mary E Enama; Robert T Bailer; Richard A Koup; Richard M Schwartz; Wataru Akahata; Gary J Nabel; John R Mascola; Theodore C Pierson; Barney S Graham; Julie E Ledgerwood
Journal:  Lancet       Date:  2014-08-14       Impact factor: 79.321

6.  An in vitro assay to study chikungunya virus RNA synthesis and the mode of action of inhibitors.

Authors:  Irina C Albulescu; Ali Tas; Florine E M Scholte; Eric J Snijder; Martijn J van Hemert
Journal:  J Gen Virol       Date:  2014-08-18       Impact factor: 3.891

7.  Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.

Authors:  Katrin Ramsauer; Michael Schwameis; Christa Firbas; Matthias Müllner; Robert J Putnak; Stephen J Thomas; Philippe Desprès; Erich Tauber; Bernd Jilma; Frederic Tangy
Journal:  Lancet Infect Dis       Date:  2015-03-02       Impact factor: 25.071

8.  DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice.

Authors:  Irina Tretyakova; Jason Hearn; Eryu Wang; Scott Weaver; Peter Pushko
Journal:  J Infect Dis       Date:  2014-02-28       Impact factor: 5.226

Review 9.  Reemergence of chikungunya virus.

Authors:  Thomas E Morrison
Journal:  J Virol       Date:  2014-07-30       Impact factor: 5.103

Review 10.  Reappearance of chikungunya, formerly called dengue, in the Americas.

Authors:  Scott B Halstead
Journal:  Emerg Infect Dis       Date:  2015-04       Impact factor: 6.883

View more
  16 in total

1.  Lack of nsP2-specific nuclear functions attenuates chikungunya virus replication both in vitro and in vivo.

Authors:  Chetan D Meshram; Tetyana Lukash; Aaron T Phillips; Ivan Akhrymuk; Elena I Frolova; Ilya Frolov
Journal:  Virology       Date:  2019-05-28       Impact factor: 3.616

2.  Epidemiological surveillance of chikungunya fever in Mexico since its introduction in 2014-2016 and identification of circulating genotypes.

Authors:  Belem Torres-Longoria; David Esaú Fragoso-Fonseca; Alma Núñez-León; María de la Luz Torres; Mauricio Vázquez-Pichardo; Noé Escobar-Escamilla; Claudia Wong-Arámbula; José Ernesto Ramírez-González; Alfonso Méndez-Tenorio; María Eugenia Castro-Mussot; María M B Moreno-Altamirano; Jorge Membrillo-Hernández; Irma López-Martínez; José Alberto Díaz-Quiñónez
Journal:  Mol Biol Rep       Date:  2021-02-01       Impact factor: 2.316

3.  Characterization of β-d-N4-Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus.

Authors:  Maryam Ehteshami; Sijia Tao; Keivan Zandi; Hui-Mien Hsiao; Yong Jiang; Emily Hammond; Franck Amblard; Olivia O Russell; Andres Merits; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 4.  Chikungunya Infection: a Global Public Health Menace.

Authors:  A J Mathew; A Ganapati; J Kabeerdoss; A Nair; N Gupta; P Chebbi; S K Mandal; Debashish Danda
Journal:  Curr Allergy Asthma Rep       Date:  2017-02       Impact factor: 4.806

5.  Novel Mutations in nsP2 Abolish Chikungunya Virus-Induced Transcriptional Shutoff and Make the Virus Less Cytopathic without Affecting Its Replication Rates.

Authors:  Ivan Akhrymuk; Tetyana Lukash; Ilya Frolov; Elena I Frolova
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

6.  Structural and Functional Characterization of Host FHL1 Protein Interaction with Hypervariable Domain of Chikungunya Virus nsP3 Protein.

Authors:  Tetyana Lukash; Tatiana Agback; Francisco Dominguez; Nikita Shiliaev; Chetan Meshram; Elena I Frolova; Peter Agback; Ilya Frolov
Journal:  J Virol       Date:  2020-12-09       Impact factor: 5.103

7.  Multiple Host Factors Interact with the Hypervariable Domain of Chikungunya Virus nsP3 and Determine Viral Replication in Cell-Specific Mode.

Authors:  Chetan D Meshram; Peter Agback; Nikita Shiliaev; Nadya Urakova; James A Mobley; Tatiana Agback; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

8.  Reduced competence to arboviruses following the sustainable invasion of Wolbachia into native Aedes aegypti from Southeastern Brazil.

Authors:  João Silveira Moledo Gesto; Gabriel Sylvestre Ribeiro; Marcele Neves Rocha; Fernando Braga Stehling Dias; Julia Peixoto; Fabiano Duarte Carvalho; Thiago Nunes Pereira; Luciano Andrade Moreira
Journal:  Sci Rep       Date:  2021-05-11       Impact factor: 4.379

Review 9.  Molecular Virology of Chikungunya Virus.

Authors:  I Frolov; E I Frolova
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.291

10.  NAP1L1 and NAP1L4 Binding to Hypervariable Domain of Chikungunya Virus nsP3 Protein Is Bivalent and Requires Phosphorylation.

Authors:  Francisco Dominguez; Nikita Shiliaev; Tetyana Lukash; Peter Agback; Oksana Palchevska; Joseph R Gould; Chetan D Meshram; Peter E Prevelige; Todd J Green; Tatiana Agback; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2021-07-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.